Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 53

1.

Progress in mucosal immunization for protection against pneumococcal pneumonia.

Gonçalves VM, Kaneko K, Solórzano C, MacLoughlin R, Saleem I, Miyaji EN.

Expert Rev Vaccines. 2019 Aug;18(8):781-792. doi: 10.1080/14760584.2019.1643719. Epub 2019 Jul 23.

PMID:
31305196
2.

Mucosal immunization with PspA (Pneumococcal surface protein A)-adsorbed nanoparticles targeting the lungs for protection against pneumococcal infection.

Rodrigues TC, Oliveira MLS, Soares-Schanoski A, Chavez-Rico SL, Figueiredo DB, Gonçalves VM, Ferreira DM, Kunda NK, Saleem IY, Miyaji EN.

PLoS One. 2018 Jan 23;13(1):e0191692. doi: 10.1371/journal.pone.0191692. eCollection 2018.

3.

Impaired expression of CXCL5 and matrix metalloproteinases in the lungs of mice with high susceptibility to Streptococcus pneumoniae infection.

Mancuso RI, Miyaji EN, Silva CCF, Portaro FV, Soares-Schanoski A, Ribeiro OG, Oliveira MLS.

Immun Inflamm Dis. 2018 Mar;6(1):128-142. doi: 10.1002/iid3.205. Epub 2017 Nov 9.

4.

Protection Elicited by Nasal Immunization with Recombinant Pneumococcal Surface Protein A (rPspA) Adjuvanted with Whole-Cell Pertussis Vaccine (wP) against Co-Colonization of Mice with Streptococcus pneumoniae.

Tostes RO, Rodrigues TC, da Silva JB, Schanoski AS, Oliveira ML, Miyaji EN.

PLoS One. 2017 Jan 19;12(1):e0170157. doi: 10.1371/journal.pone.0170157. eCollection 2017.

5.

Production and purification of an untagged recombinant pneumococcal surface protein A (PspA4Pro) with high-purity and low endotoxin content.

Figueiredo DB, Carvalho E, Santos MP, Kraschowetz S, Zanardo RT, Campani G Jr, Silva GG, Sargo CR, Horta AC, de C Giordano R, Miyaji EN, Zangirolami TC, Cabrera-Crespo J, Gonçalves VM.

Appl Microbiol Biotechnol. 2017 Mar;101(6):2305-2317. doi: 10.1007/s00253-016-7983-9. Epub 2016 Nov 26.

PMID:
27889801
6.

Polysaccharide-Specific Memory B Cells Predict Protection against Experimental Human Pneumococcal Carriage.

Pennington SH, Pojar S, Mitsi E, Gritzfeld JF, Nikolaou E, Solórzano C, Owugha JT, Masood Q, Gordon MA, Wright AD, Collins AM, Miyaji EN, Gordon SB, Ferreira DM.

Am J Respir Crit Care Med. 2016 Dec 15;194(12):1523-1531.

7.

Pulmonary dry powder vaccine of pneumococcal antigen loaded nanoparticles.

Kunda NK, Alfagih IM, Miyaji EN, Figueiredo DB, Gonçalves VM, Ferreira DM, Dennison SR, Somavarapu S, Hutcheon GA, Saleem IY.

Int J Pharm. 2015 Nov 30;495(2):903-12. doi: 10.1016/j.ijpharm.2015.09.034. Epub 2015 Sep 18.

PMID:
26387622
8.

Modulation of nasopharyngeal innate defenses by viral coinfection predisposes individuals to experimental pneumococcal carriage.

Glennie S, Gritzfeld JF, Pennington SH, Garner-Jones M, Coombes N, Hopkins MJ, Vadesilho CF, Miyaji EN, Wang D, Wright AD, Collins AM, Gordon SB, Ferreira DM.

Mucosal Immunol. 2016 Jan;9(1):56-67. doi: 10.1038/mi.2015.35. Epub 2015 Apr 29.

9.

Evaluation of a vaccine formulation against Streptococcus pneumoniae based on choline-binding proteins.

Miyaji EN, Vadesilho CF, Oliveira ML, Zelanis A, Briles DE, Ho PL.

Clin Vaccine Immunol. 2015 Feb;22(2):213-20. doi: 10.1128/CVI.00692-14. Epub 2014 Dec 17.

10.

Aerobic exercise attenuates pulmonary inflammation induced by Streptococcus pneumoniae.

Olivo CR, Miyaji EN, Oliveira ML, Almeida FM, Lourenço JD, Abreu RM, Arantes PM, Lopes FD, Martins MA.

J Appl Physiol (1985). 2014 Nov 1;117(9):998-1007. doi: 10.1152/japplphysiol.00290.2014. Epub 2014 Sep 4.

11.

Pertussis toxin improves immune responses to a combined pneumococcal antigen and leads to enhanced protection against Streptococcus pneumoniae.

Salcedo-Rivillas C, Debrie AS, Miyaji EN, Ferreira JM Jr, Raw I, Locht C, Ho PL, Mielcarek N, Oliveira ML.

Clin Vaccine Immunol. 2014 Jul;21(7):972-81. doi: 10.1128/CVI.00134-14. Epub 2014 May 7.

12.

Mapping of epitopes recognized by antibodies induced by immunization of mice with PspA and PspC.

Vadesilho CF, Ferreira DM, Gordon SB, Briles DE, Moreno AT, Oliveira ML, Ho PL, Miyaji EN.

Clin Vaccine Immunol. 2014 Jul;21(7):940-8. doi: 10.1128/CVI.00239-14. Epub 2014 May 7.

13.

Pneumococcal Surface Protein A does not affect the immune responses to a combined diphtheria tetanus and pertussis vaccine in mice.

Lima FA, Miyaji EN, Quintilio W, Raw I, Ho PL, Oliveira ML.

Vaccine. 2013 May 7;31(20):2465-70. doi: 10.1016/j.vaccine.2013.03.026. Epub 2013 Mar 26.

PMID:
23541622
14.

Controlled human infection and rechallenge with Streptococcus pneumoniae reveals the protective efficacy of carriage in healthy adults.

Ferreira DM, Neill DR, Bangert M, Gritzfeld JF, Green N, Wright AK, Pennington SH, Bricio-Moreno L, Moreno AT, Miyaji EN, Wright AD, Collins AM, Goldblatt D, Kadioglu A, Gordon SB.

Am J Respir Crit Care Med. 2013 Apr 15;187(8):855-64. doi: 10.1164/rccm.201212-2277OC. Erratum in: Am J Respir Crit Care Med. 2013 May 15;187(10):1153. Bricio Moreno, Laura [corrected to Bricio-Moreno, Laura].

15.

Serotype-independent pneumococcal vaccines.

Miyaji EN, Oliveira ML, Carvalho E, Ho PL.

Cell Mol Life Sci. 2013 Sep;70(18):3303-26. doi: 10.1007/s00018-012-1234-8. Epub 2012 Dec 27. Review.

PMID:
23269437
16.

Characterization of the antibody response elicited by immunization with pneumococcal surface protein A (PspA) as recombinant protein or DNA vaccine and analysis of protection against an intranasal lethal challenge with Streptococcus pneumoniae.

Vadesilho CF, Ferreira DM, Moreno AT, Chavez-Olortegui C, Machado de Avila RA, Oliveira ML, Ho PL, Miyaji EN.

Microb Pathog. 2012 Nov-Dec;53(5-6):243-9. doi: 10.1016/j.micpath.2012.08.007. Epub 2012 Sep 7.

17.

Controlled inflammatory responses in the lungs are associated with protection elicited by a pneumococcal surface protein A-based vaccine against a lethal respiratory challenge with Streptococcus pneumoniae in mice.

Lima FA, Ferreira DM, Moreno AT, Ferreira PC, Palma GM, Ferreira JM Jr, Raw I, Miyaji EN, Ho PL, Oliveira ML.

Clin Vaccine Immunol. 2012 Sep;19(9):1382-92. doi: 10.1128/CVI.00171-12. Epub 2012 Jul 3.

18.

Cross-reactivity of antipneumococcal surface protein C (PspC) antibodies with different strains and evaluation of inhibition of human complement factor H and secretory IgA binding via PspC.

Moreno AT, Oliveira ML, Ho PL, Vadesilho CF, Palma GM, Ferreira JM Jr, Ferreira DM, Santos SR, Martinez MB, Miyaji EN.

Clin Vaccine Immunol. 2012 Apr;19(4):499-507. doi: 10.1128/CVI.05706-11. Epub 2012 Feb 15.

19.

Economical value of vaccines for the developing countries--the case of Instituto Butantan, a public institution in Brazil.

Ho PL, Miyaji EN, Oliveira ML, Dias Wde O, Kubrusly FS, Tanizaki MM, Martins EA, Raw I.

PLoS Negl Trop Dis. 2011 Nov;5(11):e1300. doi: 10.1371/journal.pntd.0001300. Epub 2011 Nov 29. Review. No abstract available.

20.

Trends in adjuvant development for vaccines: DAMPs and PAMPs as potential new adjuvants.

Miyaji EN, Carvalho E, Oliveira ML, Raw I, Ho PL.

Braz J Med Biol Res. 2011 Jun;44(6):500-13. Epub 2011 May 13. Review.

21.

Nasal immunization of mice with Lactobacillus casei expressing the pneumococcal surface protein C primes the immune system and decreases pneumococcal nasopharyngeal colonization in mice.

Hernani Mde L, Ferreira PC, Ferreira DM, Miyaji EN, Ho PL, Oliveira ML.

FEMS Immunol Med Microbiol. 2011 Aug;62(3):263-72. doi: 10.1111/j.1574-695X.2011.00809.x. Epub 2011 May 9.

22.

Combination of pneumococcal surface protein A (PspA) with whole cell pertussis vaccine increases protection against pneumococcal challenge in mice.

Oliveira ML, Miyaji EN, Ferreira DM, Moreno AT, Ferreira PC, Lima FA, Santos FL, Sakauchi MA, Takata CS, Higashi HG, Raw I, Kubrusly FS, Ho PL.

PLoS One. 2010 May 27;5(5):e10863. doi: 10.1371/journal.pone.0010863.

23.

Protection against nasal colonization with Streptococcus pneumoniae by parenteral immunization with a DNA vaccine encoding PspA (Pneumococcal surface protein A).

Ferreira DM, Oliveira ML, Moreno AT, Ho PL, Briles DE, Miyaji EN.

Microb Pathog. 2010 Jun;48(6):205-13. doi: 10.1016/j.micpath.2010.02.009. Epub 2010 Mar 4.

PMID:
20206678
24.

Production of H5N1 (NIBRG-14) inactivated whole virus and split virion influenza vaccines and analysis of immunogenicity in mice using different adjuvant formulations.

Miyaki C, Quintilio W, Miyaji EN, Botosso VF, Kubrusly FS, Santos FL, Iourtov D, Higashi HG, Raw I.

Vaccine. 2010 Mar 16;28(13):2505-9. doi: 10.1016/j.vaccine.2010.01.044. Epub 2010 Jan 30.

PMID:
20123051
25.

Immunization of mice with single PspA fragments induces antibodies capable of mediating complement deposition on different pneumococcal strains and cross-protection.

Moreno AT, Oliveira ML, Ferreira DM, Ho PL, Darrieux M, Leite LC, Ferreira JM Jr, Pimenta FC, Andrade AL, Miyaji EN.

Clin Vaccine Immunol. 2010 Mar;17(3):439-46. doi: 10.1128/CVI.00430-09. Epub 2010 Jan 20.

26.

The immunising effect of pneumococcal nasopharyngeal colonisation; protection against future colonisation and fatal invasive disease.

Richards L, Ferreira DM, Miyaji EN, Andrew PW, Kadioglu A.

Immunobiology. 2010 Apr;215(4):251-63. doi: 10.1016/j.imbio.2009.12.004. Epub 2009 Dec 28.

PMID:
20071053
27.

Comparison of the pulmonary response against lethal and non-lethal intranasal challenges with two different pneumococcal strains.

Ferreira DM, Moreno AT, Cianciarullo AM, Ho PL, Oliveira ML, Miyaji EN.

Microb Pathog. 2009 Sep;47(3):157-63. doi: 10.1016/j.micpath.2009.05.005. Epub 2009 May 23.

PMID:
19467320
28.

Bordetella pertussis monophosphoryl lipid A as adjuvant for inactivated split virion influenza vaccine in mice.

Quintilio W, Kubrusly FS, Iourtov D, Miyaki C, Sakauchi MA, Lúcio F, Dias Sde C, Takata CS, Miyaji EN, Higashi HG, Leite LC, Raw I.

Vaccine. 2009 Jun 24;27(31):4219-24. doi: 10.1016/j.vaccine.2009.04.047. Epub 2009 May 5.

PMID:
19393709
29.

Characterization of protective mucosal and systemic immune responses elicited by pneumococcal surface protein PspA and PspC nasal vaccines against a respiratory pneumococcal challenge in mice.

Ferreira DM, Darrieux M, Silva DA, Leite LC, Ferreira JM Jr, Ho PL, Miyaji EN, Oliveira ML.

Clin Vaccine Immunol. 2009 May;16(5):636-45. doi: 10.1128/CVI.00395-08. Epub 2009 Mar 11.

30.

Nasal immunization of mice with Lactobacillus casei expressing the Pneumococcal Surface Protein A: induction of antibodies, complement deposition and partial protection against Streptococcus pneumoniae challenge.

Campos IB, Darrieux M, Ferreira DM, Miyaji EN, Silva DA, Arêas AP, Aires KA, Leite LC, Ho PL, Oliveira ML.

Microbes Infect. 2008 Apr;10(5):481-8. doi: 10.1016/j.micinf.2008.01.007. Epub 2008 Jan 20.

PMID:
18403234
31.

Recognition of pneumococcal isolates by antisera raised against PspA fragments from different clades.

Darrieux M, Moreno AT, Ferreira DM, Pimenta FC, de Andrade AL, Lopes AP, Leite LC, Miyaji EN.

J Med Microbiol. 2008 Mar;57(Pt 3):273-8. doi: 10.1099/jmm.0.47661-0.

PMID:
18287288
32.

Optimized immune response elicited by a DNA vaccine expressing pneumococcal surface protein a is characterized by a balanced immunoglobulin G1 (IgG1)/IgG2a ratio and proinflammatory cytokine production.

Ferreira DM, Darrieux M, Oliveira ML, Leite LC, Miyaji EN.

Clin Vaccine Immunol. 2008 Mar;15(3):499-505. doi: 10.1128/CVI.00400-07. Epub 2008 Jan 9.

33.

Fusion proteins containing family 1 and family 2 PspA fragments elicit protection against Streptococcus pneumoniae that correlates with antibody-mediated enhancement of complement deposition.

Darrieux M, Miyaji EN, Ferreira DM, Lopes LM, Lopes AP, Ren B, Briles DE, Hollingshead SK, Leite LC.

Infect Immun. 2007 Dec;75(12):5930-8. Epub 2007 Oct 8.

34.

Optimizing expression of Streptococcus pneumoniae surface protein a, PspA: serocross-reactivity within families of antisera induced against clades 1 and 3.

Silva M, Cabrera-Crespo J, Sbrogio-Almeida ME, Miyaji EN, Ho PL, Leite LC, Lopes AP.

Mol Biotechnol. 2007 Oct;37(2):146-54.

PMID:
17914175
35.
36.

Genetic diversity of PspA types among nasopharyngeal isolates collected during an ongoing surveillance study of children in Brazil.

Pimenta FC, Ribeiro-Dias F, Brandileone MC, Miyaji EN, Leite LC, Sgambatti de Andrade AL.

J Clin Microbiol. 2006 Aug;44(8):2838-43.

38.

Induction of systemic and mucosal immune response and decrease in Streptococcus pneumoniae colonization by nasal inoculation of mice with recombinant lactic acid bacteria expressing pneumococcal surface antigen A.

Oliveira ML, Arêas AP, Campos IB, Monedero V, Perez-Martínez G, Miyaji EN, Leite LC, Aires KA, Lee Ho P.

Microbes Infect. 2006 Apr;8(4):1016-24. Epub 2006 Jan 18.

PMID:
16549380
39.

DNA vaccines expressing pneumococcal surface protein A (PspA) elicit protection levels comparable to recombinant protein.

Ferreira DM, Miyaji EN, Oliveira ML, Darrieux M, Arêas AP, Ho PL, Leite LC.

J Med Microbiol. 2006 Apr;55(Pt 4):375-8.

PMID:
16533983
40.

DNA vaccines based on genetically detoxified derivatives of pneumolysin fail to protect mice against challenge with Streptococcus pneumoniae.

Ferreira DM, Arêas AP, Darrieux M, Leite LC, Miyaji EN.

FEMS Immunol Med Microbiol. 2006 Mar;46(2):291-7.

41.
42.

Expression and characterization of cholera toxin B-pneumococcal surface adhesin A fusion protein in Escherichia coli: ability of CTB-PsaA to induce humoral immune response in mice.

Arêas AP, Oliveira ML, Miyaji EN, Leite LC, Aires KA, Dias WO, Ho PL.

Biochem Biophys Res Commun. 2004 Aug 13;321(1):192-6.

PMID:
15358234
43.

Recombinant Mycobacterium bovis BCG expressing the Sm14 antigen of Schistosoma mansoni protects mice from cercarial challenge.

Varaldo PB, Leite LC, Dias WO, Miyaji EN, Torres FI, Gebara VC, Armôa GR, Campos AS, Matos DC, Winter N, Gicquel B, Vilar MM, McFadden J, Almeida MS, Tendler M, McIntosh D.

Infect Immun. 2004 Jun;72(6):3336-43.

44.

Adjuvant activity of Mycobacterium bovis BCG expressing CRM197 on the immune response induced by BCG expressing tetanus toxin fragment C.

Mazzantini RP, Miyaji EN, Dias WO, Sakauchi D, Nascimento AL, Raw I, Winter N, Gicquel B, Rappuoli R, Leite LC.

Vaccine. 2004 Jan 26;22(5-6):740-6.

PMID:
14741167
45.

Expression of Streptococcus pneumoniae antigens, PsaA (pneumococcal surface antigen A) and PspA (pneumococcal surface protein A) by Lactobacillus casei.

Oliveira ML, Monedero V, Miyaji EN, Leite LC, Lee Ho P, Pérez-Martínez G.

FEMS Microbiol Lett. 2003 Oct 10;227(1):25-31.

46.
47.
48.

PsaA (pneumococcal surface adhesin A) and PspA (pneumococcal surface protein A) DNA vaccines induce humoral and cellular immune responses against Streptococcus pneumoniae.

Miyaji EN, Dias WO, Gamberini M, Gebara VC, Schenkman RP, Wild J, Riedl P, Reimann J, Schirmbeck R, Leite LC.

Vaccine. 2001 Dec 12;20(5-6):805-12.

PMID:
11738744
49.

Induction of neutralizing antibodies against diphtheria toxin by priming with recombinant Mycobacterium bovis BCG expressing CRM(197), a mutant diphtheria toxin.

Miyaji EN, Mazzantini RP, Dias WO, Nascimento AL, Marcovistz R, Matos DS, Raw I, Winter N, Gicquel B, Rappuoli R, Leite LC.

Infect Immun. 2001 Feb;69(2):869-74.

50.

Recombinant Mycobacterium bovis BCG expressing pertussis toxin subunit S1 induces protection against an intracerebral challenge with live Bordetella pertussis in mice.

Nascimento IP, Dias WO, Mazzantini RP, Miyaji EN, Gamberini M, Quintilio W, Gebara VC, Cardoso DF, Ho PL, Raw I, Winter N, Gicquel B, Rappuoli R, Leite LC.

Infect Immun. 2000 Sep;68(9):4877-83. Erratum in: Infect Immun 2001 Mar;69(3):1976.

Supplemental Content

Loading ...
Support Center